(Q46545098)

23 December 2017

title

Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori (English)

1 reference

23 December 2017

1 reference

3

1 reference

23 December 2017

author name string

Caroline D Skene

series ordinal

1

1 reference

23 December 2017

Christopher Doidge

series ordinal

2

1 reference

23 December 2017

language of work or name

English

0 references

publication date

23 May 2008

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

26

1 reference

23 December 2017

issue

31

1 reference

23 December 2017

page(s)

3880-3884

1 reference

23 December 2017

Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Helicobacter pylori and gastric atrophy--cancer paradoxes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Helicobacter pylori vaccines spiral into the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Saponin-adjuvanted particulate vaccines for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

ISCOMs: an adjuvant with multiple functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

ISCOM based vaccines for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Bovine respiratory syncytial virus ISCOMs--protection in the presence of maternal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Further development of the Helicobacter pylori mouse vaccination model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Considering increased mouse stomach mass when calculating prophylactic vaccine efficacy against Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

ISCOM-based vaccines: the second decade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

Gastric adenocarcinoma: review and considerations for future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Catalase, a novel antigen for Helicobacter pylori vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.05.004

1 reference

23 December 2017

1 reference

23 December 2017